GLPG Stock Analysis: Buy, Sell, or Hold?
GLPG - Galapagos NV
$33.88
-0.25 (-0.73%)
▼
5d:
-1.51%
30d:
+3.89%
90d:
+9.57%
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 11, 2026
8d
Get Alerted When GLPG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GLPG shows positive signals but monitor for confirmation. Market pricing in 6.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: GLPG shows positive signals but monitor for confirmation. Market pricing in 6.1% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GLPG is currently trading at $33.88, which is considered slightly high relative to its 30-day fair value range of $32.83 to $34.12. From a valuation perspective, the stock is trading at a premium (Forward PE: 178.3) compared to its historical average (149.1). At these levels, the market is pricing in 6.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GLPG is showing sideways momentum. Immediate support is located at $32.13, while resistance sits at $35.06.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $28.06. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GLPG is showing sideways momentum. Immediate support is located at $32.13, while resistance sits at $35.06.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $28.06. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$32.83 -
$34.12
Company Quality Score
58/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
63.5%
All Signals
- BULLISH: Options cheap (IV 14th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 17.2% above Wall St target ($28.06)
- NEUTRAL: Trading at premium valuation - market expects 6.1% growth which is achievable
Fair Price Analysis
30-Day Fair Range
$32.83 -
$34.12
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$2.32
(6.8%)
Support & Resistance Levels
Support Level
$32.13
Resistance Level
$35.06
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
178.32
Wall Street Target
$28.06
(-17.2%)
Revenue Growth (YoY)
18.9%
Earnings Growth (YoY)
74.8%
Profit Margin
-151.9%
Valuation Premium vs History
+6.1% premium
PE vs Historical
178.3 vs 149.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.1%
(market-implied from PE analysis)
1-Year Target
$35.95
(+6%)
2-Year Target
$38.14
(+13%)
3-Year Target
$40.47
(+19%)
3-Yr Target (if PE normalizes)
(PE: 178→149)
PE COMPRESSION
$33.84
(0%)
Earnings growth offset by PE compression
Last updated: February 01, 2026 9:19 PM ET
Data refreshes hourly during market hours. Next update: 10:19 PM
Data refreshes hourly during market hours. Next update: 10:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLPG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
